Media headlines about Oxford Immunotec Global PLC (NASDAQ:OXFD) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.7112988258395 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Oxford Immunotec Global PLC (OXFD) traded up 2.42% during trading on Monday, hitting $15.69. 74,763 shares of the company’s stock traded hands. The company’s market cap is $362.06 million. Oxford Immunotec Global PLC has a 52-week low of $11.71 and a 52-week high of $19.51. The company’s 50 day moving average price is $16.14 and its 200 day moving average price is $15.48.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The company had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The business’s revenue for the quarter was up 35.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.29) EPS. Analysts expect that Oxford Immunotec Global PLC will post ($1.63) earnings per share for the current year.

OXFD has been the topic of several research reports. Cowen and Company reiterated a “buy” rating and issued a $22.00 price objective on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 price objective on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $20.25.

COPYRIGHT VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Receiving Somewhat Favorable Media Coverage, Study Shows” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/18/oxford-immunotec-global-plc-oxfd-receiving-somewhat-favorable-media-coverage-study-shows.html.

In other news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total transaction of $47,460.00. Following the sale, the director now directly owns 18,000 shares in the company, valued at approximately $284,760. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Edwardson sold 9,739 shares of Oxford Immunotec Global PLC stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $16.14, for a total value of $157,187.46. Following the sale, the chief operating officer now owns 92,905 shares in the company, valued at $1,499,486.70. The disclosure for this sale can be found here. Insiders have sold a total of 125,110 shares of company stock worth $2,059,827 over the last quarter. Company insiders own 7.58% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.